Floatz logo

s241656

KRAS G12A

Institut de Recherches Internationales ServierPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the KRAS G12A cohort.

Asset / SponsorPhaseRating
Irinotecan
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1/2CCC
Calcium folinate pentahydrate
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1/2CCC
Cetuximab
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1/2CCC
FLUOROURACILUM
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1/2CCC
PANITUMUMAB
Institut de Recherches Internationales Servier
Phase 1/2CC

View all 14 →

Same molecule, other indications

s241656 is also rated in:

histiocytic and dendritic cell neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
histiocytosisDormant
CCC
Indicative ·
48 / 100
View asset →
BRAF Gene MutationDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →